secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001171843-25-007003
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q3 revenue down 6% to $27.8M; files final Hyalofast PMA with mixed Phase III data
--------------------------------------------------------------------------------

- Q3 continuing ops rev $27.8M (-6% YoY); loss per share ($0.22); adj EPS $0.04; adj EBITDA $0.9M.
- Commercial Channel rev up 22% YoY; Integrity procedures on track to double in 2025; J&J extends Monovisc license to 2031.
- Commencing $15M share repurchase via 10b5-1 plan expected to complete by June 2026.
- Filed final Hyalofast PMA module; Phase III trial missed primary endpoints but showed significant secondary endpoint benefits.
- Hyalofast used in >35K patients globally; Breakthrough Device Designation; post-hoc analyses showed statistical significance in KOOS Pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/0001171843-25-007003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/f8k_110525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer